Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 3/20 | 0.53 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | FGB | P02675 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31756005 | 1.00 | QPCT (0.53) | QPCTKCNH3ALDH1A1LMNAKDM4E | |
| SCHEMBL27704232 | 0.85 | KDM4E (0.50) | ALDH1A1LMNAKDM4EGLATOP2B | |
| SCHEMBL28823485 | 0.80 | QPCT (0.48) | QPCTALDH1A1LMNAKDM4ESLC6A4 | |
| SCHEMBL3904434 | 0.80 | QPCT (0.49) | QPCTALDH1A1LMNAKDM4ESLC6A4 | |
| SCHEMBL30610416 | 0.78 | QPCT (0.53) | QPCTALDH1A1LMNASLC6A4SLC6A3 | |
| SCHEMBL22712390 | 0.78 | QPCT (0.53) | QPCTALDH1A1LMNASLC6A4SLC6A3 | |
| Hydrazine SCHEMBL28348678 | 0.78 | QPCT (0.50) | QPCTALDH1A1LMNASLC6A4SLC6A3 | |
| SCHEMBL6571157 | 0.77 | TDO2 (0.38) | QPCTKCNH3ALDH1A1SCN9ACHRM3 | |
| SCHEMBL20522374 | 0.77 | QPCT (0.49) | QPCTALDH1A1LMNAKDM4ESLC6A4 | |
| SCHEMBL20522286 | 0.77 | QPCT (0.50) | QPCTALDH1A1LMNAKDM4ESLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | QPCT 3/4885KCNH3 1601/4885ALDH1A1 1681/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | QPCT 2/4885KCNH3 1598/4885ALDH1A1 1490/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | QPCT 2/4885KCNH3 2098/4885ALDH1A1 1415/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | QPCT 3/4885KCNH3 1845/4885ALDH1A1 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.